HER-2 Amplification Probe

Location: San Francisco, CA
Date: 2021-02-23

http://www.health-carebiotech.com/molecular-diagnostic-probe/fluorescence-in-situ-hybridization-probes/her-2-amplification-probe.html
HER-2 Gene Amplification FISH ProbeProduct Advantages:?1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour.?2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.3.Reproducibility: Different laboratories test results are highly reproducible.About HER-2 geneHER-2 gene is located on the 17q12 of the human chromosome 17. It is one of the members of the epidermal growth factor receptor (EGFR/ErbB) family. It has tyrosine kinase activity and participates in the signal transduction of cell growth and differentiation. The carcinogenic mechanism of HER2 oncogene includes inhibiting apoptosis, promoting cell proliferation, increasing the invasiveness of tumor cells, and promoting tumor angiogenesis and lymphangiogenesis. 20% the expression of HER2 gene was positive in breast cancer and 12% gastric cancer.?Probe DescriptionThe HER2 gene amplification probe uses orange-red dye to mark the HER-2 gene region .and the green dye to mark the centromeric region of chromosome 17 (CEP17) .The HER2 gene tagged region is located at the 17q12-q21.1, and the CEP17 probe is labeled with a specific alpha satellite sequence.?Clinical SignificanceHER2 gene amplification can be found in many cancers such as breast cancer, hernia, small cell lung cancer, ovarian cancer, prostate cancer, colorectal cancer, salivary glands, etc., and is more common in breast cancer.Breast cancer is one of the most common malignant tumors in women. The incidence rate accounts for 7-10% of all malignant tumors in the whole body. About 20-35% breast cancer patients have HER2 gene amplification high protein expression. Breast cancer patients are recommended routine detection of HER2 gene status.Size Specifications?References Sauter G,et al.J Clin Oncol 27:1323-1333,2009.?Mass R,et al.Clinical Breast Cancer,Vol 6, No. 3, 240-246, 2005.?Allison M,Nature Biotechnology 28 (2):117-119, 2010.Press M,et al,Clinical Cancer Research 2005; 11(18) September 15, 2005

Contact Info: Healthcarebio@aliyun.com